The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study (SCORE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00105027 |
|
Recruitment Status :
Completed
First Posted : March 4, 2005
Results First Posted : January 19, 2011
Last Update Posted : May 2, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Macular Edema, Cystoid Retinal Vein Occlusion | Other: Standard Care Drug: intravitreal triamcinolone injection | Phase 3 |
Macular edema is a major cause of vision loss in patients with CRVO and BRVO. Both CRVO and BRVO are common retinal problems and are caused by a blockage in one of the large retinal veins (central retinal vein occlusion - CRVO) or smaller retinal veins (branch retinal vein occlusion - BRVO). Currently, there is no effective treatment for macular edema associated with CRVO and standard care treatment is observation. Grid laser photocoagulation may be effective for some patients for macular edema associated with BRVO, but many patients derive limited benefit from this treatment. Therefore, the development of new treatment modalities for macular edema caused by these two conditions is an important research goal.
Over the last several years, many patients with macular edema from CRVO and BRVO have been treated with an injection of a type of steroid called triamcinolone directly into the eye. This type of injection is called an intravitreal injection. The triamcinolone preparation commonly injected into the eye is Kenalog and is FDA-approved only for use in muscles and joints. The SCORE Study will use a formulation of triamcinolone made specifically for the eye.
The SCORE Study is a multicenter, randomized, Phase III trial to compare the effectiveness and safety of standard care versus triamcinolone injection(s) for the treatment of macular edema associated with CRVO and BRVO. In each of the two disease areas, 630 participants will be randomized (similar to a flip of a coin) in a 1:1:1 ratio to one of three groups: standard care, intravitreal triamcinolone 4 mg, or intravitreal triamcinolone 1 mg. After randomization, participants will be examined every 4 months through 3 years to collect ophthalmic information, including visual acuity, intraocular pressure, optical coherence tomography, and fundus photography . Fluorescein angiography will be performed at 4, 12 and 24 months. Repeat intravitreal injections of triamcinolone and repeat laser treatment will be provided as clinically indicated based on protocol-specific guidelines.
The primary outcome is improvement by 15 or more letters from baseline in best-corrected ETDRS visual acuity score at the 12-month visit. Secondary outcomes include changes from baseline in best-corrected ETDRS visual acuity score, changes in retinal thickness as assessed by stereoscopic color fundus photography and optical coherence tomography, and adverse ocular outcomes.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 682 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema |
| Study Start Date : | October 2004 |
| Actual Primary Completion Date : | February 2009 |
| Actual Study Completion Date : | February 2009 |
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: CRVO Observation |
Other: Standard Care
CRVO: observation; BRVO: standard care |
| Active Comparator: CRVO 1 mg dose triamcinolone acetonide |
Drug: intravitreal triamcinolone injection
1 mg dose |
| Active Comparator: CRVO 4 mg dose triamcinolone acetonide |
Drug: intravitreal triamcinolone injection
4 mg |
| Active Comparator: BRVO standard care |
Other: Standard Care
CRVO: observation; BRVO: standard care |
| Active Comparator: BRVO 1 mg dose triamcinolone acetonide |
Drug: intravitreal triamcinolone injection
1 mg dose |
| Active Comparator: BRVO 4 mg dose triamcinolone acetonide |
Drug: intravitreal triamcinolone injection
4 mg |
- The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit [ Time Frame: Change from baseline to 12 months ]Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
- Individuals, 18 years of age or older, willing to provide consent may be eligible for the SCORE Study.
Exclusion Criteria: refer to SCORE Study website at https://web.emmes.com/study/score/ for listing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00105027
| United States, Wisconsin | |
| University of Wisconsin | |
| Madison, Wisconsin, United States, 53711 | |
| Study Chair: | Michael S. Ip, M.D. | University of Wisconsin, Madison |
Documents provided by The EMMES Corporation:
Additional Information:
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | The EMMES Corporation |
| ClinicalTrials.gov Identifier: | NCT00105027 History of Changes |
| Other Study ID Numbers: |
NEI-99 5U10EY014351-05 ( U.S. NIH Grant/Contract ) 5U10EY014404 ( U.S. NIH Grant/Contract ) 5U10EY014352 ( U.S. NIH Grant/Contract ) |
| First Posted: | March 4, 2005 Key Record Dates |
| Results First Posted: | January 19, 2011 |
| Last Update Posted: | May 2, 2018 |
| Last Verified: | April 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Data sets will be provided to qualified investigators under a Data Use Agreement. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
| Time Frame: | to be set forth in data use agreement |
| Access Criteria: | qualified investigators |
Keywords provided by The EMMES Corporation:
|
macular edema central retinal vein occlusion (CRVO) branch retinal vein occlusion (BRVO) |
Additional relevant MeSH terms:
|
Edema Macular Edema Retinal Vein Occlusion Signs and Symptoms Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases Venous Thrombosis Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |
Triamcinolone hexacetonide Triamcinolone Triamcinolone Acetonide Triamcinolone diacetate Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |